Barrington Research Rates Bioventus (BVS) buy, $14 Price Target

Barrington Research maintains its Buy rating on Bioventus Inc. with a $14 price target, a 48.31% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 9:03 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barrington Research rated Bioventus Inc. ($BVS) "buy" with a $14 price target on June 30, 2026.

Since the rating, $BVS is up 21.7% after 1 week, up 39.6% after 1 month and up 40.9% to date (from the $9.44 close on Jun 30, 2026).

BVS Bioventus Inc.

$13.30 +84.47% year to date

Daily close · Oct 16, 2026

Key Points

Barrington Research reiterated its Buy rating for Bioventus Inc. (BVS) with a $14 price target on June 30, 2026.
Barrington Research's $14 price target implies 48.31% upside from Bioventus Inc.'s ($BVS) current $9.44 share price.
Bioventus Inc. shares traded near $9.78 on Tuesday, with a market cap of $662.6 million and a P/E ratio of 23.9.
Analysts from Barrington Research, Canaccord Genuity, and Craig-Hallum maintain Buy ratings with targets between $14 and $16.

Get $BVS trade alerts by text

We text you when insiders, Congress or big funds trade $BVS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bioventus Inc. alert may contain errors. Disclosures

Barrington Research reiterated its Buy rating for Bioventus Inc. (NasdaqGS: BVS) on June 30, 2026. Analyst Michael Petusky set a price target of $14 for the medical device company. This reiteration comes as Bioventus shares traded near $9.78 on Tuesday.

Bioventus Inc. Stock Down 26.9%

Shares of NasdaqGS:BVS traded near $9.78 on Tuesday. Bioventus Inc. has a market cap of approximately $662.6 million, with a P/E ratio of 23.9 and a forward P/E of 10.8. The stock's 52-week range is between $5.81 and $11.25. The company's 50-day moving average is $9.59, while the 200-day moving average is $8.24. Bioventus maintains a current ratio of 1.69 and a quick ratio of 1.06, with a debt-to-equity ratio of 123.1.

12-month forecast

$BVS price target

Bioventus Inc. daily closes and this analyst's $14 target. Not advice.

Recent Earnings

Bioventus reported revenue of $576.3 million, showing a growth of 6.6%. The company achieved an EPS of $0.41, with a net margin of 4.9% and a return on equity of 16.5%. Investors are looking forward to the next earnings report scheduled for August 4, 2026.

Insider Buying and Selling at Bioventus Inc.

On June 3, 2026, several insiders at Bioventus Inc. made purchases of 25,146 shares each, including Philip Cowdy, Mary Kay Ladone, Pat Beyer, Martin Sutter, and Guido Neels. William Hawkins also bought 30,994 shares. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

On June 30, 2026, Barrington Research maintained its Buy rating for Bioventus with a $14 price target. Earlier in June, on the 16th, Canaccord Genuity also maintained its Buy rating with a $15 target. Craig-Hallum had previously set a Buy rating with a $16 target. The consensus among analysts is a Buy rating, with an average target price of $14.8 based on five analyst opinions.

About Bioventus Inc.

Bioventus Inc. is a healthcare company specializing in medical devices aimed at pain relief and musculoskeletal therapies. Based in Durham, North Carolina, the company offers a range of products including intra-articular injections and peripheral nerve stimulation devices. Bioventus also provides surgical solutions and bone graft substitutes. Led by CEO Mr. Robert E. Claypoole, the company employs approximately 940 people and serves healthcare institutions and distributors globally.

Bottom Line

Barrington Research's reiteration of a Buy rating for Bioventus Inc. highlights analyst confidence in the company's growth prospects. As Bioventus continues to expand its product offerings, investors will be watching upcoming earnings and market developments closely. Analyst ratings and price targets provide valuable insights, though they reflect past performance and expectations.